Adma Biologics Inc (ADMA) |
|
Price: $5.9400
$-0.05
-0.835%
|
Day's High:
| $6.045
| Week Perf:
| -4.5 %
|
Day's Low: |
$ 5.92 |
30 Day Perf: |
10 % |
Volume (M): |
2,879 |
52 Wk High: |
$ 6.42 |
Volume (M$): |
$ 17,102 |
52 Wk Avg: |
$4.06 |
Open: |
$6.03 |
52 Wk Low: |
$2.95 |
|
|
Market Capitalization (Millions $) |
1,290 |
Shares
Outstanding (Millions) |
217 |
Employees |
256 |
Revenues (TTM) (Millions $) |
258 |
Net Income (TTM) (Millions $) |
-28 |
Cash Flow (TTM) (Millions $) |
-35 |
Capital Exp. (TTM) (Millions $) |
5 |
Adma Biologics Inc
Adma Biologics Inc. is a publicly traded biopharmaceutical company based in New Jersey, United States. It is primarily focused on the development and commercialization of plasma-based biologics for the treatment of a variety of infectious diseases and disorders. Adma Biologics was founded in 2004 and has since then become a leader in the plasma-derived therapeutics field. The company has developed and marketed a number of FDA-approved intravenous immunoglobulin (IVIG) products for the treatment of primary humoral immunodeficiency disease. IVIG products manufactured by Adma Biologics are derived from human plasma collected from a variety of qualified sources in the US, and are purified and treated to remove any viral, bacterial, or other contaminants that could compromise the productes safety and efficacy. In addition to IVIG products, Adma Biologics has also developed Bivigame and Nabi-HBe for the treatment of Hepatitis B and C in specific patient populations. The company is also developing products for the treatment of pneumococcal and other bacterial infections. The companyes proprietary technology, called RI-002, enables the production of highly concentrated, pure polyclonal human immunoglobulin G (IgG) for the treatment and prevention of a wide range of viral and bacterial infections. The technology has the potential to revolutionize the production of high-quality, pure biologic products that are safe and effective for human use. Overall, Adma Biologics is dedicated to improving the lives of patients with serious and life-threatening medical conditions by developing innovative therapies that address unmet medical needs. The company's research and development efforts are focused on creating new treatments for infectious diseases, autoimmune disorders, and other serious medical conditions, with the goal of providing safe and effective therapies that can improve the overall quality of life for patients.
Company Address: 465 State Route 17 Ramsey 7446 NJ
Company Phone Number: 478-5552 Stock Exchange / Ticker: NASDAQ ADMA
ADMA is expected to report next financial results on March 22, 2024. |
|
|
|
|
|
|
Stock Performances by Major Competitors |
|
|
Adma Biologics Inc
Adma Biologics Inc, a biopharmaceutical company specializing in plasma-derived antibody products, has reported a deficit per share of $-0.07 in the fourth quarter of 2023, an increase from the previous quarter. However, the company's revenue saw a significant uptick of 49.427% to $74.69 million compared to the same period the year before. This revenue growth comes as a positive surprise amidst a -4.90% contraction in the Biotechnology & Pharmaceuticals sector. The company's net deficit for the financial interval closing December 31, 2023, was $-17.645 million, a larger figure than the previous year. Additionally, Adma Biologics Inc saw an increase in inventories to $172.9 million, as well as a decline in accounts receivable to $27.4 million. For the full year of 2023, the company reported a net deficit of $-28.24 million and revenue of $257.94 million.
|
Financing Agreement
Published Mon, Dec 18 2023 9:06 PM UTC
ADMA Biologics Secures $135 Million Non-Dilutive Refinancing Deal with Ares Management, Consolidating Debt and Bolstering Financial Stability In a major move to strengthen its financial position, ADMA Biologics, a biopharmaceutical company focused on the development and commercialization of plasma-derived antibody products, has successfully closed a non-dilutive refinanc...
|
Adma Biologics Inc
ADMA Biologics Inc, a leading biopharmaceutical company, has reported impressive financial results for the fiscal third quarter of 2023. The company has shown significant growth in various key indicators, suggesting a promising outlook for future profitability and market performance. Compared to the same quarter in the previous year, ADMA managed to turn a profit, recording earnings per share (EPS) of $0.01. This is a substantial improvement from the negative EPS of $-0.08 in the prior year. Net profit per share also witnessed a positive turnaround, increasing from $-0.03 to a positive figure. These figures highlight the company's ability to effectively manage its operations and generate profits.
|
Adma Biologics Inc
Adma Biologics Inc, within the Biotechnology & Pharmaceuticals industry, has delivered positive financial results for the second quarter of the 2023 earnings season. Despite a loss per share, the company showcased robust revenue growth and exhibited resilience against the challenges faced by its industry peers. This article aims to delve into the details of these financial results and provide insights into the company's performance. Financial Results Analysis: 1. Earnings per Share (EPS): - In the second quarter of 2023, Adma Biologics Inc incurred a loss of $0.03 per share, an improvement from the loss of $0.07 per share recorded a year earlier. - Sequentially, there was no change in EPS, remaining at $0.03 per share.
|
Adma Biologics Inc
The stock market is a volatile environment where investors are often faced with unpredictable changes. Therefore, before making any investment decisions, it is advisable to conduct thorough research on the company or organization in question to better understand the financial position and profitability. Right now, the stock market has received reports stating that Adma Biologics Inc has seen a tremendous increase in revenue by 95.558% to $56.91 million, which has helped to cut losses to $-0.03 per share, from $-0.13 in the corresponding reporting season a year ago. Additionally, the Q4 revenue climb is encouraging, with 13.869% from $49.98 million and an improvement in EPS from -$0.05 per share. Despite the encouraging figures, investors should remain cautious. It is essential to consider all relevant factors affecting Adma Biologics Inc before investing. For instance, it is worth examining what led to the deficit faced by the company in the first quarter of 2023 in contrast to a year ago. With that in mind, investors should seek to identify the challenges that the company experienced and how the management team intends to address them. By doing so, investors can make sound and informed investment decisions.
|
Per Share |
Current |
Earnings (TTM) |
-0.12 $ |
Revenues (TTM) |
1.19 $
|
Cash Flow (TTM) |
- |
Cash |
0.24 $
|
Book Value |
0.62 $
|
Dividend (TTM) |
0 $ |
|
Per Share |
|
Earnings (TTM) |
-0.12 $
|
Revenues (TTM) |
1.19 $ |
Cash Flow (TTM) |
- |
Cash |
0.24 $
|
Book Value |
0.62 $ |
Dividend (TTM) |
0 $ |
|
|
|
|